Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jan 10, 2012

166_ip_2012-01-10_9d06770c-cd30-417b-96a3-9752578f0785.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Commerzbank German Investment Seminar

January 9 – 11, 2012

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE & Co. KGaA

Fresenius Group: Financial Results

5-year CAGR: 10%

EBIT5-year CAGR: 14%

Net Income5-year CAGR: 19%

Group financial results before APP-transaction-related special items

Fresenius Group: Financial Results

S
l
a
e
s		 E
B
I
T		 1
N
i
t
e
n
c
o
m
e
/
Q
1
3
1
1
-		 €
1
2
0
8
9
m
,		 €
1
8
6
2
m
,		 €
5
6
5
m
G
h
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 %
5		 %
9		 %
1
7
G
h
l
t
t
t
r
o
a
a
c
a
w
u
t
c
r
r
e
n
c
r
a
e
s
u
y		 2
%		 5
%		 1
4
%

1Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Group: Financial Results by Business Segment

/
Q
1
3
1
1
-		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
H
l
i
e
o
s		 F
i
r
e
s
e
n
u
s
V
d
a
m
e
S
l
a
e
s
G
h
t
r
o
w		 \$
S
U
9
4
7
3
m
,
%
7		 €
2
9
5
0
m
,
%
8		 €
1
9
5
0
m
,
%
6		 €
4
8
0
m
%
7
-
E
B
I
T
G
h
t
r
o
w		 \$
U
S
8
8
1
4
m
,
%
7		 €
6
1
3
m
%
1
0		 €
1
9
5
m
%
1
3		 €
2
2
m
%
8
-

Fresenius Kabi: Update Q1-3/11

    • 3% organic sales growth in Q3, leading to 9% growth in Q1-3; outstanding Q1-3 EBIT margin of 20.8%
    • 9% organic sales growth outside North America
  • 15% growth in Emerging Markets China as largest contributor (+21%)
  • 19% growth in I.V. drugs broad-based portfolio
    • 10% organic sales growth in NA driven by new products and drug shortages
  • Q3: -10% due to exceptionally high Q3/10 base
    • Fully on track for 2011 guidance – Q4 yoy growth expected at mid single-digit rates

Fresenius Kabi: Save the Date!

Fresenius Helios: Update Q1-3/11

  • Operating business in great shape: 4% organic sales growth; 70 bps EBIT margin increase to 10.0%; Q3 EBIT margin of 11.0% at all-time high
  • Hospital acquisitions provide significant growth
  • German market update: 15 to 20 projects YTD pending/concluded
  • Acquisition of Damp Group 7th largest German private hospital operator
  • Acquisition of sixth maximum-care hospital (Duisburg)
  • 2012 DRG-inflator increases to 1.48% (2011: 0.9%)

HELIOS hospital network pro forma, including Damp Group and Duisburg Hospital

Fresenius Vamed: Update Q1-3/11

    • Sales and earnings fully in line with expectations
    • Negative sales growth due to 2010 Ukraine project and Middle East/North Africa unrest

    • 10% sales growth adjusted for Ukraine/Middle East/North Africa

    • Excellent Q3 order intake of €171 million
  • -€98 million hospital turnkey project, Russia
  • -€42 million hospital turnkey project, Germany
    • On track to achieve 2011 sales and EBIT guidance

Fresenius Group: 2011 Outlook by Business Segment

F
i
r
e
s
e
n
u
s
d
i
l
C
M
e
c
a
a
r
e		 S
l
h
t
a
e
s
g
r
o
w
i
N
t
e
n
c
o
m
e		 \$
U
S
1
3
0
b
n
~
\$
S
U
1,
0
7
0
1,
0
9
0
m
–
F
i
r
e
s
e
n
u
s
K
b
i
a		 S
l
h
t
a
e
s
g
r
o
w
E
B
I
T
i
m
a
r
g
n		 8
0
8
5
%
i
o
r
g
a
n
c
–
2
0
%
≥
i
F
r
e
s
e
n
u
s
H
l
i
e
o
s		 S
l
h
t
a
e
s
g
r
o
w
E
B
I
T		 %
i
3
5
o
r
g
a
n
c
–
€
2
0
2
0
6
7
m
–
F
i
r
e
s
e
n
s
u
V
d
a
m
e		 S
l
h
t
a
e
s
g
r
o
w
E
B
I
T
h
t
g
r
o
w		 0
%
l
d
f
5
o
e
n
o
r
a
n
g
e
w
–
-
0
5
%
–
F
i
r
e
s
e
n
s
u
B
i
h
t
o
e
c		 E
B
I
T		 €
3
0
m
~
-

Fresenius Group: 2011 Outlook

R
h
t
e
e
n
e
g
r
o
v
u
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 6
%
~
1
N
i
h
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 8
%
1
~
C
a
p
e
x		 %
f
G
l
5
o
r
o
u
p
s
a
e
s
~

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Group: Where are we Heading Mid term?

Additional growth through small / mid-sized acquisitions

Focus on quality and cost leadership

Mid-term stretch financial goal: Group net income >€1 bn by 2014

Attachments

Fresenius Group: Profit and Loss Statement

G
h
t
t
r
o
w
a
c
o		 t
t
t
n
s
a
n
r
a
e
s
€
m		 Q
/
3
1
1		 Q
/
1
3
1
1
-		 Q
/
3
1
1		 Q
/
1
3
1
1
-
S
l
a
e
s		 4
0
8
5
,		 1
2
0
8
9
,		 3
%		 5
%
E
B
I
T		 6
5
5		 1
8
6
2
,		 %
5		 %
9
N
i
t
t
t
e
n
e
r
e
s		 2
1
5
-		 0
4
1
-		 8
%		 2
%
I
t
n
c
o
m
e
a
x
e
s		 1
6
3
-		 4
5
1
-		 %
2
-		 %
8
-
1
N
i
t
e
n
c
o
m
e		 2
0
2		 5
6
5		 %
9		 %
1
7

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Group: Cash Flow

€
m		 /
Q
3
1
1		 L
T
M
i
M
a
r
g
n		 /
Q
3
1
0		 L
T
M
i
M
a
r
g
n		 G
h
t
r
o
w
Y
Y
o
O
i
C
h
l
t
F
p
e
r
a
n
g
a
s
o
w		 5
0
6		 %
1
0
6		 5
4
1		 %
1
1
4		 %
6
-
C
(
)
t
a
p
e
x
n
e		 8
3
1
-		 %
4
4
-		 1
7
1
-		 %
4
5
-		 %
7
-
F
C
h
F
l
r
e
e
a
s
o
w
(
)
b
f
i
i
i
d
d
i
i
d
d
t
e
o
r
e
a
c
q
s
o
n
s
a
n
e
n
s
u
v		 3
2
3		 2
%
6		 3
0
7		 9
%
6		 3
%
1
-
(
)
i
i
i
A
t
t
c
q
s
o
n
s
n
e
u		 3
5
-		 6
8
-		 %
4
9
D
i
i
d
d
v
e
n
s		 3
5
-		 1
2
-		 1
9
2
%
-
F
C
h
F
l
r
e
e
a
s
o
w
(
)
f
i
i
i
d
d
i
i
d
d
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 2
5
3		 %
3
3
-		 2
9
0		 %
3
1		 %
1
3
-

Cash Flow Development LTM

€
m		 C
O
i
F
t
p
e
r
a
n
g		 (
)
C
t
a
p
e
x
n
e		 1
C
F
h
F
l
r
e
e
a
s
o
w
L
T
M
Q
/
1-
3
1
1		 L
T
M
M
i
a
r
g
n		 L
T
M
Q
/
1-
3
1
1		 L
T
M
M
i
a
r
g
n		 L
T
M
Q
/
1-
3
1
1		 L
T
M
M
i
a
r
g
n
3
9
5		 1
3
8
%		 (
)
1
6
7		 (
)
4
%
5		 3
6
3		 9
3
%
2
9
7		 %
1
1
3		 (
)
1
2
8		 (
)
%
4
9		 1
6
9		 3
%
6
4
1
1
-		 %
1
6
-		 (
)
6		 (
)
9
%
0		 1
7
-		 2
%
5
-
Co
/
te
rp
or
a
O
he
t
r		 3
0
-		 /
n
a		 (
)
1
2		 /
n
a		 4
2
-		 /
n
a
l.
F
M
C
ex
c		 7
9
5		 2
%
1
1
8		 (
)
3
2
2		 (
)
%
4
4		 4
7
3		 2
%
7
4
G
ro
up		 2
1
7
1
,		 0
%
1
6		 (
)
7
1
7		 (
)
%
4
4		 0
0
1
4
,		 2
%
6

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 8.7% excluding €61 million of Capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

Debt excludes Mandatory Exchangeable Bonds which came to maturity on August 14, 2011

Fresenius Kabi: Strong Organic Sales Growth

€
m		 Q
/
1
3
1
1
-		 Q
/
1
3
1
0
-		 O
i
r
g
a
n
c
G
h
t
r
o
w
I
f
i
T
h
n
u
s
o
n
e
r
a
p
y		 6
6
5		 2
8
6		 3
%
I.
V
D
r
u
g
s		 0
1
7
6
,		 9
8
2		 %
1
4
C
l
i
i
l
N
i
i
t
t
n
c
a
u
r
o
n		 8
5
5		 8
9
7		 9
%
/
M
d
i
l
D
i
e
c
a
e
v
c
e
s
T
f
i
T
h
l
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 3
5
4		 3
2
4		 9
%
l
l
T
t
o
a
s
a
e
s		 2
9
5
0
,		 2
7
2
3
,		 %
9

Fresenius Kabi: Strong Organic Sales Growth

€
m		 /
Q
3
1
1
1
-		 /
Q
3
1
1
0
-		 O
i
r
g
a
n
c
G
h
t
r
o
w
E
u
r
o
p
e		 3
0
1
6
,		 2
1
6
4
,		 %
6
h
i
N
A
t
o
r
m
e
r
c
a		 7
5
5		 7
3
0		 %
1
0
A
i
P
i
f
i
s
a
a
c
c
-		 5
1
1		 4
3
6		 %
1
8
/
L
i
A
i
A
f
i
t
a
n
m
e
r
c
a
r
c
a		 3
2
4		 2
9
3		 %
1
1
T
l
l
t
o
a
s
a
e
s		 2
9
5
0
,		 2
7
2
3
,		 %
9

Fresenius Kabi: Excellent EBIT Growth

€
m		 /
Q
1
3
1
1
-		 /
Q
1
3
1
0
-		 G
h
t
r
o
w
E
u
r
o
p
e
i
M
a
r
g
n		 2
8
4
%
2
0.
9		 2
6
9
%
2
1.
3		 6
%
N
h
A
i
t
o
r
m
e
r
c
a
i
M
a
r
g
n		 2
8
8
%
3
8.
1		 2
2
4
%
3
3.
2		 9
%
1
i
i
f
i
/
i
i
/
f
i
A
P
L
A
A
t
s
a
a
c
c
a
n
m
e
r
c
a
r
c
a
-
M
i
a
r
g
n		 1
6
9
2
0.
2
%		 1
3
4
1
8.
4
%		 %
2
6
C
d
C
R
D
t
t
&
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 2
8
1
-		 8
8
-		 %
4
5
-
T
l
E
B
I
T
t
o
a		 6
1
3		 5
5
7		 %
1
0
M
i
a
r
g
n		 2
0
8
%		 2
0
5
%

Fresenius Helios: Excellent Sales and EBIT Growth

€
m		 Q
/
1
3
1
1
-		 Q
/
1
3
1
0
-		 G
h
t
r
o
w
T
l
l
t
o
a
s
a
e
s		 1
9
5
0
,		 1
8
4
0
,		 %
6
E
B
I
T
E
b
l
i
h
d
l
i
i
f
l
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
M
i
a
r
g
n		 1
9
9
0.
%
1
4		 1
7
2
9.
3
%		 %
1
6
A
i
i
i
t
c
q
u
s
o
n
s
(
)
l
i
d
i
1
t
c
o
n
s
o
a
o
n
y
r
<		 4
-
T
l
E
B
I
T
t
o
a		 9
1
5		 2
1
7		 3
%
1
M
i
a
r
g
n		 1
0
0
%		 9
3
%

Fresenius Helios: 2010 Restructuring Plan

i
f
l
i
Y
t
e
a
r
s
n
p
o
r
o
o
1
<		 1 2 3 4 5 5
>		 T
l
t
o
a
N
f
l
i
i
o.
o
c
n
c
s		 - - 6 4 7 - 2
5		 4
2
(
)
R
€
e
v
e
n
u
e
m		 - - 8
1
6		 2
6
1		 1
7
5		 - 1,
6
0
7		 2,
2
2
9
T
t
a
r
g
e
(
)
E
B
I
T
D
A
i
%
m
a
r
g
n		 - 3.
0		 0
6.		 9.
0		 2.
0
1		 0
1
5.		 0
1
5.
(
)
E
B
I
T
D
A
€
m		 - - 1
1.
2		 2
3.
5		 2
0.
9		 - 2
4
1.
1		 2
9
6.
7
R
d
t
e
p
o
r
e
(
)
E
B
I
T
D
A
i
%
m
a
r
g
n		 - - 0
4.		 0.
8
1		 9
1
1.		 - 8
1
5.		 3.
9
1
(
)
E
B
I
T
D
A
€
m		 - - 7.
5		 8.
2
2		 8
2
0.		 - 2
5
4.
2		 3
1
0.
7
N
f
l
i
i
t
t
o.
o
c
n
c
s
a
r
g
e
>		 - - 3 3 4 - 1
4		 2
4
N
f
l
i
i
t
t
o.
o
c
n
c
s
a
r
g
e
<		 - - 3 1 3 - 1
1		 8
1

Fresenius Helios: Performance Indicators

/
Q
3
1
1
1
-		 /
Q
3
0
1
1
-		 C
h
a
n
g
e
1
f
h
i
l
N
t
o
o
o
s
p
a
s
l
i
i
A
t
c
u
e
c
a
r
e
c
n
c
s
-
l
i
i
P
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
4
4
4
2
0		 6
2
4
2
2
0		 %
3
%
5
%
0
1
f
b
d
N
o
o
e
s
A
l
i
i
t
c
u
e
c
a
r
e
c
n
c
s
-
l
i
i
P
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 1
9
3
3
6
,
8
1
5,
6
9
3,
4
6
7		 1
8
5
6
4
,
1
5,
0
9
7
3,
4
6
7		 %
4
%
5
%
0
2
d
i
i
A
m
s
s
o
n
s
(
)
A
i
i
t
t
t
c
u
e
c
a
r
e
n
p
a
e
n
-		 8
4
7
2,
3
9		 4
5
1,
7
3
9		 %
5
2
O
c
c
p
a
n
c
u
y
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 7
9
%		 8
1
%
2
(
)
A
l
h
f
d
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
e
c
a
r
e
u
-
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 6.
7
2
9.
6		 7.
0
2
9.
5

Dec 31, 2010

2Clinics in Germany

Fresenius Vamed: Sales and EBIT in Line with Expectations

€
m		 Q
/
1
3
1
1
-		 Q
/
1
3
1
0
-		 G
h
t
r
o
w
j
b
i
P
t
r
o
e
c
u
s
n
e
s
s
S
i
b
i
e
r
v
c
e
u
s
n
e
s
s		 3
1
1
1
6
9		 3
5
1
1
6
6		 %
1
1
-
%
2
T
l
l
t
o
a
s
a
e
s		 8
4
0		 5
1
7		 %
7
-
T
l
E
B
I
T
t
o
a
M
i
a
r
g
n		 2
2
%
4
6		 2
4
%
4
6		 8
%
-
1
O
d
i
k
t
r
e
r
n
a
e
1
O
d
b
k
l
r
e
r
a
c
o
g		 3
3
5
7
7
5		 4
1
8
2
8
0
1		 %
2
0
-
%
3
-

Project business only

2Dec 31, 2010

Share Information

Share key facts

Number of shares1 163,043,629 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Exchange OTC-market Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053Structure Sponsored Level I ADR

as of October 31, 2011

Financial Calendar

2
0
2
2
0
2
1
1		 R
F
i
l
Y
2
0
t
1
1
e
p
o
r
o
n
s
c
a
e
a
r
0
3
0
2
0
2
5
1		 t
R
2
0
2
t
1
s
t
1
e
p
o
r
o
n
q
u
a
r
e
r
0
2
0
2
1
1
5
1		 /
A
l
G
l
M
i
F
k
f
M
i
t
t
n
n
u
a
e
n
e
r
a
e
e
n
g
r
a
n
u
r
a
n
,
0
0
8
2
0
2
1
1		 t
R
h
l
f
2
0
2
t
1
s
1
e
p
o
r
o
n
a
3
0
2
0
2
1
1
1		 d
t
R
3
2
0
2
t
1
s
r
t
1
e
p
o
r
o
n
q
u
a
r
e
r
–

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.